๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huizhou
Clinical trial register · China

Clinical Trials in Huizhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 8 Huizhou 7 Beijing 3 Shanghai 3 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou8 Huizhou7 Beijing3 Shanghai3 Hangzhou1
All 5 locations
Target enrolment
to

Trials with a site in Huizhou

7 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
NCT06462092Leptomeningeal Metastases
Guangzhou Medical University
Phase 1/2
34
Huizhou
2026-01-01
Recruiting
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
NCT06296745Leptomeningeal Metastasis
Guangzhou Medical University
Phase 2
36
Huizhou
2025-09-01
Recruiting
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
NCT06809517Leptomeningeal Metastasis, Intrathecal Drug Delivery
Guangzhou Medical University
Phase 1/2
34
Huizhou
2025-03-18
Active, closed
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
NCT06809530Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4
Guangzhou Medical University
Phase 1/2
34
Beijing, Huizhou, Shanghai
2025-03-17
Active, closed
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
NCT06762080Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2
36
Huizhou, Beijing, Shanghai
2025-03-07
Active, closed
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
NCT06462222Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2
45
Huizhou, Beijing, Shanghai
2024-06-30
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/huizhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies with a site in Huizhou that also match the filters currently applied.

How many clinical trials are recruiting in Huizhou?

4 of the 7 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huizhou), 7 studies
PhaseStudiesRecruitingShare
Phase 1/25271.4%
Not applicable1114.3%
Phase 21114.3%

Most active sponsors

Lead sponsors with the most studies (Huizhou)
Lead sponsorStudiesRecruiting
Guangzhou Medical University74
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.